| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |
Abstract |
|---|
|
|
|---|
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder
characterized by fibroblast proliferation and extracellular matrix accumulation. However, studies on fibroblast growth rate and collagen synthesis have given contradictory results. Here we analyzed fibroblast growth rate by a formazan-based chromogenic assay; fibroblast apoptosis by in situ end labeling
(ISEL) and propidium iodide staining; percent of
-smooth
muscle actin (
-SMA) positive cells by fluorescence-activated
cell sorter; and
1-(I) collagen, transforming growth factor
(TGF)-
1, collagenase-1, gelatinases A and B, and tissue inhibitor of metalloproteinase (TIMP)-1, -2, -3, and -4 expression by
reverse transcriptase/polymerase chain reaction in fibroblasts
derived from IPF and control lungs. Growth rate was significantly lower in IPF fibroblasts compared with controls (13.3 ± 38.5% versus 294.6 ± 57%, P < 0.0001 at 13 d). Conversely, a
significantly higher percentage of apoptotic cells was observed in IPF-derived fibroblasts (ISEL: 31.9 ± 7.0% versus
15.5 ± 7.6% from controls; P < 0.008).
-SMA analysis revealed a significantly higher percentage of myofibroblasts in
IPF samples (62.8 ± 25.2% versus 14.8 ± 11.7% from controls;
P < 0.01). IPF fibroblasts were characterized by an increase in
pro-
1-(I) collagen, TGF-
1, gelatinase B, and all TIMPs' gene
expression, whereas collagenase-1 and gelatinase A expression showed no differences. These results suggest that fibroblasts from IPF exhibit a profibrotic secretory phenotype, with
lower growth rate and increased spontaneous apoptosis.
| |
Introduction |
|---|
|
|
|---|
Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP) is a progressive and usually lethal lung disorder characterized by fibroblast proliferation and abnormal accumulation of extracellular matrix (ECM) molecules, especially fibrillar collagens (1). An important feature in IPF/UIP is the presence of fibroblast foci, widely dispersed throughout the lung parenchyma (1). Fibroblast foci seem to represent microscopic zones of acute lung injury where fibroblasts migrate, proliferate, and contribute to the accumulation of ECM molecules in the damaged alveolus. Subsequently, abnormal remodeling of lung architecture results from interstitial and intraluminal deposition of connective tissue (2).
However, studies dealing with the proliferative characteristics and collagen synthesis capacity in fibroblasts obtained from normal human lungs and IPF lungs are scant and results have been inconclusive (3). Thus, for example, Jordana and colleagues (3) showed that human lung fibroblasts derived from fibrotic tissues proliferate significantly faster than do those obtained from normal lungs. On the other hand, Raghu and associates (4) found that fibroblast proliferation was highest in cells derived from areas of early fibrosis compared with normal areas, whereas the lowest proliferation was observed in cells obtained from dense fibrosis.
Additionally, fibroblasts are not a homogeneous population, and in the last decade the concept of phenotypic diversity has emerged. Thus, phenotypically distinct populations of lung fibroblasts that differ in surface markers, receptor expression, cytoskeletal arrangement, and cytokine profile have been described (6, 7). In this context we have recently demonstrated significant differences in the growth rate of normal human lung fibroblast subpopulations separated by size, with an inverse relationship between cell size and growth rate (8).
Myofibroblasts are a unique subpopulation of fibroblasts that express features of smooth-muscle differentiation.
-Smooth muscle actin (
-SMA)-positive fibroblasts
increase in IPF lungs and constitute the major component
of the fibroblasts' foci (1, 2). In addition, these cells acquire an aggressive phenotype and seem to be the main
subset responsible for collagen accumulation (9).
On the other hand, the abnormal ECM remodeling observed in IPF lungs is at least partially due to an imbalance between some components of the matrix metalloproteinase (MMP) family, i.e., collagenase-1 (MMP-1), gelatinases A and B (MMP-2 and -9, respectively), and the tissue inhibitors of metalloproteinase (TIMPs) (10). Fibroblasts are good candidates to play an important role in this aberrant remodeling process because they are responsible for the exaggerated secretion of most of the ECM components; however, their participation through MMP and/or TIMP expression is largely unknown.
In this study we examined the following in lung fibroblasts derived from IPF patients and control human lungs:
growth rate; apoptotic index; percent of myofibroblasts;
and
1-(I) collagen, MMP-1, MMP-2, MMP-9, TIMP-1,
TIMP-2, TIMP-3, TIMP-4, and transforming growth factor
(TGF)-
gene expression.
| |
Materials and Methods |
|---|
|
|
|---|
Materials
Materials for cell isolation and culture were from GIBCO BRL
(Rockville, MD). Trypsin, propidium iodine (PI), and fluorescein isothiocianate (FITC)-conjugated monoclonal antibody (mAb)
to
-SMA (clone B4A) were obtained from Sigma Chemical Co.
(St. Louis, MO). Avidin-FITC, FITC-conjugated antimouse immunoglobulin G, deoxyribonuclease (DNAse)-free ribonuclease
(RNAse) (cytometry grade), and proliferation reagent WST-1
were from Boehringer Mannheim (Indianapolis, IN). All other
chemicals were of reagent grade.
Fibroblast Isolation and Culture
Primary human lung fibroblasts were obtained in our laboratory as previously described (13). Briefly, fibroblasts were derived from lung tissue obtained from IPF patients (n = 5) by open lung biopsy. IPF was diagnosed as described elsewhere, including the characteristic morphology of UIP (1). Patients (three male and two female; four nonsmokers and one ex-smoker) aged 57 ± 5 yr (mean ± standard deviation [SD]) were inpatients at Instituto Nacional de Enfermedades Respiratorias, Mexico DF, Mexico. Time elapsed to first visit after the beginning of symptoms, usually progressive dyspnea, was 22 ± 6 mo. All patients showed a restrictive functional pattern (forced vital capacity: 57 ± 10% of predicted; total lung capacity: 62 ± 9% of predicted) and hypoxemia at rest (53 ± 7 mmHg; normal values for Mexico City: 59 ± 8 mmHg), worsening with exercise. Lung samples were taken by open lung biopsy usually 1 wk after hospital admission. None of the patients had been treated with corticosteroids or immunosuppressive drugs at the time of biopsy. Control fibroblasts (n = 5) were derived from lungs of patients undergoing lobectomy/pneumonectomy for removal of a primary lung tumor which showed no histologic evidence of disease. Lung fibroblasts were isolated by trypsin dispersion, and cells were grown in Ham's F-12 medium (GIBCO Laboratories, Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) (GIBCO BRL). Fibroblasts (passages 5-8) were cultured at 37°C in 5% CO2/95% air in T-25 cm2 Falcon flasks, using Ham's F-12 medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 g/ml streptomycin.
Growth Rate Assay
Fibroblasts were plated in 96-well culture plates at a cell density of 15 × 103 cells/well and incubated at 37°C in 5% CO2/95% air in Ham's F-12 medium supplemented with 10% FBS. After 24 h, the medium was replaced using 1% or 10% FBS and the growth rate was followed for 13 d.
Cell number was determined using the cell proliferation reagent WST-1 (Boehringer Mannheim) as previously described (8). WST-1 is a tetrazolium salt cleaved by the mitochondria of viable cells to yield a soluble formazan chromophore. The medium in corresponding wells was replaced with fresh medium, and the dye solution was added to each well according to manufacturer's instructions. Absorbance was measured on an enzyme-linked immunosorbent assay (ELISA) plate reader at a wavelength of 450 nm using a reference wavelength of 620 nm. Absorbance changes were taken as percentage of growth rate increase related to basal values (Day 0).
Flow Cytometry Analysis for
-SMA and Apoptosis
Flow cytometry analysis was performed on a Partec CA-III flow cytometer equipped with a 25-mW argon ion laser for excitation at 488 nm. PI fluorescence was acquired through a 610-nm long-pass filter, and fluorescent FITC through an EM 520 band-pass filter. After standardization with fluorescence microspheres (Coulter, Hialeah, FL), amplifier gains were not changed throughout an experiment.
Fibroblasts for cytometry analyses were grown at mid-log
phase in culture media supplemented with 10% FBS. Cells were
recovered by trypsyn/ethylenediaminetetraacetic acid (EDTA)
digestion, centrifuged, and fixed in ice-cold 70% ethanol while
shaking for 5 min, and stored at
20°C until assayed.
For apoptosis analysis, a bivariate assay of in situ end labeling (ISEL) versus log forward angle light scatter (FALS, an index of cell size [8]) was performed. Cells were labeled with biotinylated deoxyuridine triphosphate (dUTP) and detected with avidin-FITC as described by Gorczyca and coworkers (14). Briefly, cells were washed with phosphate-buffered saline (PBS) for 10 min at 4°C, and incubated with saline sodium citrate buffer containing 1% bovine serum albumin (BSA) for 45 min at 37°C. After washing with PBS, cells were incubated with 100 µl ISEL buffer containing Bio-dUTP for 2 h at 17°C. Finally, fibroblasts were washed again with PBS and incubated with 100 µl avidin-FITC/ PBS for 45 min at 37°C.
To evaluate
-SMA expression, fibroblasts were incubated
for 1 h at 37°C with FITC-conjugated monoclonal antihuman
-SMA antibody diluted 1:400 in 1% BSA in PBS, pH 7.3, with
DNAse-free RNAse (25 µg/ml). DNA distribution experiments
were conducted with PI as described earlier (15).
Microscopy and Image Analysis of
-SMA
Fibroblasts were grown at mid-log phase in culture media supplemented with 10% fetal calf serum (FCS) and were labeled
with antihuman
-SMA (clone BA4) antibody in a way similar to
that performed for flow cytometry analysis. Photomicrography
was accomplished with an Olympus EMT-2 epifluorescence
phase-contrast microscope equipped with band-pass filters for
detection of FITC and fitted with color and gray-scale charge-coupled device cameras. Cell diameters of
-SMA-positive and
-negative cells were determined by automated measurement of
ferret diameters of 50 cells/group with the image-analysis program MOCHA (Jandel Scientific, San Rafael, CA).
Fluorescence Microscopy for Apoptosis
Detection of apoptotic cells with PI was conducted as described earlier after digestion of ethanol-fixed cells with DNAse-free RNAse in PBS containing 5 µg/ml PI (8, 15). In these assays detached cells were retained by centrifugation of the 24-well culture vessels during fixation with 70% ethanol for at least 30 min at 4°C; red fluorescence intensity (> 590 nm) of chromatin-bound PI is proportional to DNA content, allowing visualization of chromatin condensation. For quantitation, fragmented nuclei were scored as a percentage of total nuclei in a minimum of four microscopic fields per culture vessel; at least four culture vessels per fibroblast strain were scored. Data from three normal and three fibrotic strains were compiled and are reported as means ± SD.
Reverse Transcription/Polymerase Chain Reaction
Total RNA from lung fibroblasts was isolated according the acid guanidium isothiocianate/phenol chloroform extraction method. Complementary DNA (cDNA) from IPF (n = 3) and control (n = 3) fibroblasts was synthesized by reverse transcription of 5 µl total RNA, using a cDNA synthesis kit (GIBCO BRL).
Polymerase chain reaction (PCR) amplification (Perkin-Elmer 9600, Perkin-Elmer, Branchburg, NJ) was performed with a cDNA working mixture in a 25-µl reaction volume containing 20 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM MgCl2, 200 µM deoxynucleotide triphosphates, 1 µM specific 5' and 3' primers and 1 U Taq DNA polymerase (Perkin-Elmer).
To quantify the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), a competitor was constructed by cutting with NcoI an internal fragment of 155 base pairs (bp) of a GAPDH cDNA of originally 1,233 bp cloned in a PBR 322 plasmid. The modified GAPDH cDNA was subsequently religated. The competitor (c) GAPDH sequence was obtained by PCR amplification of the modified plasmid using the primers for GAPDH. The competitor size was 240 bp.
Four-fold serial dilutions of the standard competitor (5, 10, 15, and 20 pg) were coamplified with a constant amount of cellular cDNA (1 µl). Cycling conditions were: 95°C for 10 min for one cycle; 95°C for 30 s, 58°C for 30 s, and 72°C for 120 s for 40 cycles; and the final incubation at 72°C for 7 min. Aliquots (5 µl) of the PCR product were resolved in 1.5% agarose gel containing ethidium bromide. Band intensities were quantitated by scanning densitometry using a Kodak digital science electrophoresis documentation and analysis system 120 (Kodak, Rochester, NY). The logarithm of GAPDH/cGAPDH ratio was plotted as a function of the logarithm of known cGAPDH amount. The point of equivalence represents the concentration of GAPDH in the cDNA sample. Dilutions were performed to reach 50 to 750 fentograms of GAPDH for each amplification as specified in Table 1.
|
cDNA was amplified with specific primers (16-21, Table 1) by PCR. Amplification conditions for all reactions were done at: 94°C for 5 min for one cycle; 94°C for 30 s, 55 to 60°C for 30 s, and 72° C for 30 s for a number of cycles (Table 1); and the final incubation at 72°C for 5 min. Aliquots (5 µl) of the PCR products were resolved in 1.5% agarose gel containing ethidium bromide. Band intensities were quantitated by scanning densitometry.
Collagen Synthesis Assay
Collagen synthesis was evaluated according to Peterkofsky and
Diegelmann (22). Fibroblasts (2.5 × 105 per well) were cultured
in six-well tissue culture multiwell plates in Ham's F-12 medium
supplemented with 10% FBS. After 24 h, the medium was replaced by fresh serum-free medium containing 15 µCi/ml [3H]proline (New England Nuclear, Boston, MA), 50 µg/ml ascorbic acid, and 50 µg/ml
-aminopropionitrile. After 6 h labeling, supernatants were collected and dialyzed against distilled water
containing protease inhibitors (25 mM N-ethylmaleimide, 0.1 mM
phenylmethylsulfonyl fluoride, and 10 mM EDTA) and 0.02%
sodium azide. Samples were lyophilized and resuspended in 50 mM
Tris-HCl and 10 mM CaCl2 (pH 7.6). Aliquots were incubated
with or without 36 µg/ml bacterial collagenase (Sigma type VII)
for 3 h at 37°C and precipitated with cold 10% trichloroacetic
acid and 0.5% tanic acid. Collagen synthesis was evaluated in the
supernatants and noncollagenous proteins in the precipitates
after HCl hydrolysis. Samples were counted in a scintillation
counter (Beckman LS6000 SE). Collagen synthesis was calculated as: % collagen synthesis = disintegrations per min (dpm)
collagen × 100/(dpm noncollagen protein × 5.4) + dpm collagen.
TGF-
1 Quantification
Measurement of TGF-
1 protein in fibroblast conditioned media
was performed by using a commercial sensitive and specific
ELISA, following the manufacturer's instructions (R&D Systems,
Minneapolis, MN). TGF-
1 was expressed as picograms per microgram of protein.
Statistical Analysis
Results are expressed as means ± SD. Comparisons were made using a Student's t test for unpaired observations. Values of P < 0.05 were considered statistically significant.
| |
Results |
|---|
|
|
|---|
Growth Rate Analysis
To determine the growth rate of control and IPF-derived fibroblasts, cell number was determined up to 13 d, using the cell proliferation reagent WST-1. As shown in Figure 1A, fibroblasts derived from IPF patients exhibited a significantly lower growth rate when compared with control cells from the fourth day until the end of the experiment (IPF: 13.3 ± 38.5% versus 294.6 ± 57% in controls at 13 d; P < 0.0001). Similar results were obtained when cells were incubated in media containing 10% FCS (Figure 1B).
|
Flow Cytometry Analysis of Apoptosis and
-SMA Expression
ISEL of fragmented DNA was used to evaluate the percent of fibroblasts displaying spontaneous apoptosis. Cells cultured in medium supplemented with 10% FCS at mid- log phase were harvested and subjected to cytofluorometric analysis of ISEL in relation to cell size (Figure 2). As shown in Table 2, fibroblasts derived from IPF lungs displayed a significant increase in the percent of apoptotic cells when compared with controls (IPF versus controls: 31.4 ± 6.9% versus 15.0 ± 7.4%; P < 0.008). In addition, the presence of apoptotic cells was analyzed by PI staining (Figures 3A and 3B). As shown in Figure 3C, a significant increase of apoptosis was observed in IPF fibroblasts (430 ± 49% versus 100 ± 16% in controls; P < 0.01).
|
|
|
The proportion of
-SMA immunoreactive cells was
analyzed by immunocytochemistry followed by microscopy image analysis and cytometry analysis in relation to
DNA content, as shown in Figure 4. As seen in Table 2,
several strains of lung fibroblasts derived from IPF patients
showed a significant increase in the percent of
-SMA-
positive cells when compared with control lung fibroblasts (IPF versus controls: 62.8 ± 25.2 versus 14.8 ± 11.6%; P < 0.01).
|
Additionally, the cell diameters of
-SMA-positive and
-negative cells were determined by automated measurement of ferret diameters of 50 cells/group with the image-analysis program MOCHA. Results showed that in both
IPF and control fibroblast strains, cells immunoreactive to
-SMA exhibited a significantly higher diameter than did
negative cells (IPF: 38.1 ± 8.2 µm versus 26.9 ± 7.4 µm, P < 0.05; controls: 35.8 ± 7.0 µm versus 25.7 ± 5.8 µm, P < 0.05). This result was consistent with immunocytochemical observation where
-SMA immunoreactive cells appeared
larger than negative cells (Figures 4A and 4B).
IPF and Control Fibroblast Gene Expression
Semiquantitative assessment of messenger RNA (mRNA) of selected molecules expressed by IPF and control fibroblasts was done by serial dilutions of cDNA samples adjusted to equal quantified housekeeping gene GAPDH. Densities of bands of PCR products achieved with these primers were analyzed by agarose gel electrophoresis (Figure 5). GAPDH band intensities were quantitated by scanning densitometry (controls: 5,314 ± 96; IPF fibroblasts: 5,377 ± 85), demonstrating that the DNA used from different cell lines was similar.
|
IPF-derived fibroblasts consistently revealed a higher
expression of
1-(I) collagen gene as compared with control fibroblasts (Figure 5A). The expression increased almost 2-fold when quantitated by scanning densitometry
(9,418 ± 1,217 versus 5,173 ± 1,559; P < 0.02). When these
cell lines were analyzed for collagen synthesis a similar result was observed (53.1 ± 5.2% versus 28.6 ± 3.7%; P < 0.01). Concerning TGF-
1 expression (Figure 5A), mRNA
transcripts were usually more abundant in IPF than in control fibroblasts (12,881 ± 2,033 versus 6,902 ± 2,782; P < 0.05); however, at the protein level, results were heterogeneous and no differences were observed (96 ± 23 versus
120 ± 34 pg/mg protein).
Collagenase-1 (MMP-1) was expressed by one out of three control cell strains and equally by one from three IPF-derived fibroblast cell strains with no difference in the net intensity of the band in the collagenase-expressing cell lines. No significant differences were found among fibroblasts expressing gelatinase A (MMP-2) (3,922 ± 664 in normal versus 6,037 ± 1,641 in IPF fibroblasts). By contrast, gelatinase B (MMP-9) was expressed in two out of three IPF-derived strains (30,414 ± 1,416) and faintly (3,615) by one out of three control cell lines (Figure 5A).
Results of reverse transcriptase (RT-PCR) for all four TIMPs are illustrated in Figure 5B. TIMP-1 revealed a 2-fold increase in IPF compared with control fibroblasts (75,195 ± 10,119 versus 38,479 ± 13,846; P < 0.02). TIMP-2 was also highly expressed in IPF fibroblasts showing a 2-fold increase in net intensity in IPF as compared with controls (20,935 ± 6,451 versus 9,449 ± 4,322; P = 0.05). Likewise, TIMP-3 and TIMP-4 were mainly expressed in IPF-derived fibroblasts and faintly detectable in one control cell strain.
| |
Discussion |
|---|
|
|
|---|
IPF is a progressive and usually fatal lung disorder characterized by the occurrence of widely scattered small clusters of fibroblasts, presumably provoked by multiple microscopic lung injuries, and abnormal tissue remodeling (1).
A growing body of evidence has demonstrated that there is phenotypic and behavioral heterogeneity among tissue fibroblasts. Myofibroblasts, which express features of smooth-muscle differentiation, constitute one of these subpopulations and are usually increased in human and experimental lung fibrosis (2, 9).
In the present study, fibroblasts derived from IPF lungs
displayed a marked increase in the percentage of myofibroblasts, paralleling the in vivo observations. As examined by fluorescence-activated cell sorter and immunocytochemistry, most of the fibroblasts derived from IPF
lungs expressed
-SMA. The cell origin of lung myofibroblasts remains unknown, but interstitial fibroblasts and
smooth muscle-like cells of the alveolar duct septal tips
are considered as a potential source (23). Increased myofibroblasts in the multiple fibroblast foci of IPF lungs may
have a number of deleterious consequences, primarily
contributing to active parenchymal contraction, decreased compliance, and distorted architecture (2). Actually, myofibroblasts play a critical role in healing because they express high levels of
-SMA, form tight adhesions to the
substrate, and arrange the stress fibers along the long axis,
facilitating tissue contraction and reducing the amount of
denuded surface area of wounded tissue (24). In addition,
myofibroblasts produce apoptotic factor(s) for alveolar
epithelial cells in vitro (25), and have been localized close
to denuded alveolar epithelium in vivo (26). Moreover, it
has been suggested that myofibroblasts may be responsible for most of the increased lung collagen gene expression in pulmonary fibrosis (9). Nevertheless, this last observation had not been documented in vitro. Raghu and
colleagues (5) found that fibroblasts from normal and fibrotic lungs synthesize similar amounts of collagen even
when stimulated with TGF-
. In our study, however, fibroblasts derived from IPF lungs, usually presenting high
proportions of
-SMA-positive cells, expressed higher levels of type I collagen mRNA and synthesized higher amounts
of collagen compared with normal lung fibroblasts.
On the other hand, IPF fibroblasts showed a marked decrease of growth rate when compared with lung fibroblasts derived from normal subjects. The cell kinetic assay showed a marked difference from the fourth day on. This finding differs from those previously reported. Thus, Jordana and associates (3) showed that primary fibroblasts derived from IPF patients proliferated faster than did normal lung fibroblasts; whereas Raghu and coworkers (4), who obtained fibroblasts from different areas of the same fibrotic lung, found a higher rate of proliferation in cells derived from inflammatory areas and the lowest in fibroblasts from dense fibrotic scars. Given the new histologic classification of IPF (1), it is not certain whether IPF fibroblasts in those studies were obtained from UIP cases.
Our results substantiate unpublished observations found
repeatedly over many years in our laboratory. Usually, fibroblast strains derived from IPF lungs are very difficult to
grow in vitro and exhibit a limited number of duplications.
The reduced growth rate of the IPF fibroblasts could have
several possible explanations. Thus, for example, it has
been shown that rat lung myofibroblast differentiation in
vitro results in reduced telomerase activity (27). The decreased expression of this enzyme may account for a reduced proliferative capacity. Likewise, we have previously demonstrated that myofibroblasts, when separated by
gravity sedimentation, are usually large cells that grow
markedly slower than intermediate or small size fibroblasts (8). Coincidentally, in this study we also observed
that the diameters of the
-SMA-positive cells, independently if derived from normal or IPF lungs, were significantly larger than those of
-SMA-negative cells.
In addition, slower growth rate may be also explained
by an increase in programmed cell death. Our findings
support this notion because IPF fibroblasts exhibited a
higher basal rate of spontaneous apoptosis than did normal cells. In studies of primary fibroblasts isolated from
normal human lung, Akamine and colleagues (6) identified two subpopulations which were isolated on the basis of differential expression of the receptor for C1q, one of
the first subcomponents of complement. The fibroblast
subsets separated by C1q receptor expression displayed
two distinct morphologies: spindle-shaped cells with elongated processes (high binding), or larger and more flattened cells (6). The subgroups also differed in rates of proliferation and especially collagen synthesis, both under
basal conditions and after inhibition by interferon-
or
stimulation by TGF-
. More interesting in the context of
our findings, the low C1q-binding subset also displayed a
poor rate of growth in culture despite containing a higher
percentage of cycling cells identified by flow cytometry (6).
This paradox might be explained by a higher rate of spontaneous apoptosis within this subpopulation, which exhibits the same morphologic characteristics (large and flat) as the "large" subgroup identified in our earlier work (8).
Regardless, in this report we showed that IPF fibroblast
isolates contain an increased subpopulation of myofibroblasts and exhibit decreased proliferative capacity and an
increased rate of spontaneous apoptosis. A number of cytokines might participate in the induction of this apoptosis,
including interleukin-1
, which has been reported to induce apoptosis and inhibit cell proliferation (28). In addition, the increased basal apoptosis might be related to the
production by myofibroblasts of angiotensin peptides (29), which induce apoptosis in a variety of cell types, including
alveolar epithelial cells of the lung (29, 30). With regard to
the molecules analyzed in this study, although primarily
related to ECM remodeling, some of them may also contribute to increased apoptosis. Particularly, overexpression
of TIMP-3 induces programmed cell death in a variety of
cell types (31). Inhibition of tumor necrosis factor-
-converting enzyme may account at least partially for its ability
to induce apoptosis (31).
The determination of which of these factors is involved in the induction of fibroblast apoptosis, and which phenotypes within the lung fibroblast isolate undergo apoptosis, will be an interesting topic for future experiments.
The final stage of IPF is an extensive structural disorganization of the lung parenchyma with the subsequent progressive loss of the alveolar-capillary units. The molecular
mechanisms behind this erratic tissue remodeling that results in an exaggerated ECM accumulation have not been
elucidated but likely involve a loss in the highly regulated
balance between MMPs and TIMPs (10). In this context there were no differences in collagenase-1 mRNA expression, which corroborates previous findings with MMP-1
protein levels in IPF and control fibroblasts (32). With regard to gelatinases, MMP-2 has been shown to be constitutively expressed in lung fibroblasts and we did not find differences in IPF and normal lung-derived cells. However,
normal lung fibroblasts usually do not express MMP-9 in
vitro and thus our recent finding
corroborated in this study
that fibroblasts obtained from IPF lungs strongly
expressed the MMP-9 transcript was quite interesting (12).
Further, the expression of gelatinase B was closely related
with the percent of myofibroblasts (12). Gelatinase B expression may have a role in basement membrane disruption and fibroblast migration into the alveolar spaces.
The gene expression of all four TIMPs was usually increased in fibroblasts derived from IPF lungs. Although
different TIMPs bind tightly to most MMPs, differences in
inhibitory properties, expression patterns, and other properties
such as association with latent MMPs, cell growth-
promoting activity, cell survival-promoting activity, and
apoptosis
have been reported (31, 33). In this context,
upregulation of TIMP gene expression could contribute to
a prevailing lung fibrotic microenvironment by inhibiting
MMP activity and matrix degradation; supporting this
point of view, we recently found in vivo that in IPF lungs
there is higher interstitial expression of TIMPs compared
with collagenases (12). On the other hand, because TIMPs
may play a role in regulating apoptosis or cell survival, the
increase of TIMP expression may also contribute to the
pathogenic processes observed in IPF lungs by either increasing proliferation of some cell populations or inducing
the death of others. In this context, it is interesting to emphasize that TIMP-2 is almost exclusively expressed by fibroblasts/myofibroblasts in the characteristic fibroblast foci
considered to be the sites of ongoing alveolar epithelial injury and activation associated with evolving fibrosis (11, 12).
Fibroblast TIMP-2 expression could be associated with collagenase inhibitory effect, but also with activation of latent
gelatinase A and stimulation of fibroblast proliferation.
TIMP-3 is singular because it binds strongly to insoluble
extracellular components, mainly heparan sulfate. It has
been observed to have antiadhesive properties in fibroblasts, and TIMP-3 overexpression can induce apoptosis
(31). TIMP-3 is the only TIMP to inhibit members of the
ADAM (a disintegrin and metalloprotease domain) and
to restrain shedding of L-selectin (31). Interestingly, it has
been reported that the levels of TIMP-3 mRNA were elevated in systemic sclerosis fibroblast cell strains (34). Studies on TIMP-4 are scanty and their functional activities,
besides MMP inhibition, are essentially unknown. Recent evidence demonstrates a temporal relationship between
upregulation of TIMP-4 and the onset of collagen deposition in injured arterial walls, suggesting an important role
in the proteolytic balance of the vasculature (35).
Certainly, other cell types besides fibroblasts/myofibroblasts may play a role in the protease-antiprotease imbalance in IPF. Thus, resident cells (i.e., alveolar epithelial cells and endothelial cells) as well as those derived from the inflammatory response are able to produce different MMPs and TIMPs in vivo. Particularly, MMP-1, MMP-2, MMP-9, and TIMP-2 have been detected in epithelial cells close to fibroblast foci. MMP-1 has also been observed in alveolar macrophages, MMP-9 in neutrophils, TIMP-1 and TIMP-3 in interstitial macrophages, and TIMP-4 in plasma-cells (11). Therefore, during the development of IPF, ECM remodeling is regulated by a complex interplay among epithelial and endothelial cells, fibroblasts, and inflammatory cells, and the ECM in the local mielieu.
In summary, although the number of fibroblast strains explored in this study is small, our in vitro findings correlate with some previous in vivo observations and suggest that fibroblasts/myofibroblasts from IPF lungs exhibit a profibrotic secretory phenotype with lower growth rate and increased spontaneous apoptosis.
| |
Footnotes |
|---|
Address correspondence to: Annie Pardo, Ph.D., Apartado Postal 21-630, Coyoacán , Mexico DF 04000, Mexico.
(Received in original form August 21, 2000 and in revised form November 21, 2000).
Abbreviations:
-smooth muscle actin,
-SMA; base pair(s), bp; complementary DNA, cDNA; competitor GAPDH, cGAPDH; deoxyribonuclease, DNase; extracellular matrix, ECM; fetal bovine serum, FBS; fetal calf serum, FCS; fluorescein isothiocyanate, FITC; glyceraldehyde-3-phosphate dehydrogenase, GAPDH; idiopathic pulmonary fibrosis, IPF; in situ end labeling, ISEL; matrix metalloproteinase, MMP; messenger RNA, mRNA; phosphate-buffered saline, PBS; polymerase chain reaction, PCR;
propidium iodide, PI; ribonuclease, RNase; reverse transcriptase, RT;
standard deviation, SD; transforming growth factor, TGF; tissue inhibitor
of metalloproteinase, TIMP; usual interstitial pneumonia, UIP.
| |
References |
|---|
|
|
|---|
1.
Katzenstein, A. L. A., and
J. L. Myers.
1998.
Idiopathic pulmonary fibrosis.
Clinical relevance of pathologic classification.
Am. J. Respir. Crit. Care
Med.
157:
1301-1315
2. Kuhn, C., and J. A. McDonald. 1991. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am. J. Pathol. 138: 1257-1265 [Abstract].
3. Jordana, M., J. Schulman, C. McSharry, L. B. Irving, M. T. Newhouse, G. Jordana, and J. Gauldie. 1988. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am. Rev. Respir. Dis. 137: 579-584 [Medline].
4. Raghu, G., Y. Y. Chen, V. Rusch, and P. S. Rabinovitch. 1988. Differential proliferation of fibroblasts cultured from normal and fibrotic human Lung. Am. Rev. Respir. Dis. 138: 703-708 [Medline].
5.
Raghu, G.,
S. Masta,
D. Meyers, and
A. S. Narayanan.
1989.
Collagen synthesis by normal and fibrotic human lung fibroblasts and the effect of
transforming growth factor-
.
Am. Rev. Respir. Dis.
140:
95-100
[Medline].
6. Akamine, A., G. Raghu, and S. Narayanan. 1992. Human lung subpopulations with different C1q binding and functional properties. Am. J. Respir. Cell Mol. Biol. 6: 382-389 .
7. Phipps, R. P. 1992. Pulmonary Fibroblast Heterogeneity. CRC Press, Boca Raton, FL.
8.
Uhal, B. D.,
C. Ramos,
I. Joshi,
A. Bifero,
A. Pardo, and
M. Selman.
1998.
Cell size, cell cycle, and
-smooth muscle actin expression by primary human lung fibroblasts.
Am. J. Physiol.
275:
L998-L1005
9. Zhang, K., M. D. Rekhter, D. Gordon, and S. H. Phan. 1994. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. Am. J. Pathol. 145: 114-125 [Abstract].
10. Hayashi, T., W. G. Stetler-Stevenson, M. V. Fleming, N. Fishback, M. N. Koss, L. A. Liotta, V. J. Ferrans, and W. D. Travis. 1996. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. Am. J. Pathol. 149: 1241-1256 [Abstract].
11. Fukuda, Y., M. Ishizaki, S. Kudoh, M. Kitaichi, and N. Yamanaka. 1998. Localization of matrix metalloproteinases-1, -2, and -9, and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab. Invest. 78: 687-698 [Medline].
12.
Selman, M.,
V. Ruiz,
S. Cabrera,
L. Segura,
R. Ramírez,
R. Barrios, and
A. Pardo.
2000.
TIMP 1, 2, 3 and 4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment?
Am. J. Physiol.
279:
L562-L574
13.
Becerril, C.,
A. Pardo,
M. Montaño,
C. Ramos,
R. Ramírez, and
M. Selman.
1999.
Acidic fibroblast growth factor (FGF-1) induces an antifibrogenic
phenotype in human lung fibroblasts.
Am. J. Respir. Cell Mol. Biol.
20:
1020-1027
14.
Gorczyca, W.,
J. Gong, and
Z. Darzynkiewicz.
1993.
Detection of DNA
strand breaks in individual apoptotic cells by in situ terminal deoxynucleotidyl transferase and nick translation assay.
Cancer Res.
53:
1945-1951
15.
Uhal, B. D., and
D. E. Rannels.
1991.
DNA distribution analysis of Type II
pneumocyte by laser flow cytometry: technical considerations.
Am. J. Physiol.
261:
L296-L306
16. Janowska-Wieczorek, A., L. A. Marquez, A. Matsuzaki, H. Hashmi, R. Haroon, L. M. Laratt, L. M. Boshkov, A. R. Turner, M. C. Zhang, D. R. Edwards, and A. E. Kossokowska. 1992. Expression of matrix metalloproteinases (MMP-2 and 9) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute myelogenous leukaemia blasts: comparison with normal bone marrow cells. Br. J. Haematol. 105: 402-411 .
17. Takagi, M., S. Santavirta, H. Ida, M. Ishii, K. Akimoto, K. Saotome, and Y. T. Konttinen. 1998. The membrane-type-matrix metalloproteinase/matrix metalloproteinase-2/tissue inhibitor of metalloproteinase-2 system in periprosthetic connective-tissue remodeling in loose total hip prostheses. Lab. Invest. 78: 735-742 [Medline].
18.
Finlay, G. A.,
L. R. O'Driscoll,
K. J. Russell,
E. M. D'Arcy,
J. B. Masterson,
M. X. FitzGerald, and
C. M. O'Connor.
1997.
Matrix metalloproteinase
expression and production by alveolar macrophages in emphysema.
Am. J. Respir. Crit. Care Med.
156:
240-247
19.
Lemjabbor, H.,
P. Gosset,
E. Lechapt-Zatcman,
M. L. Franco-Montoya,
B. Wallaert,
A. Harf, and
C. Lafuma.
1999.
Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis.
Am. J. Respir. Cell Mol. Biol.
20:
903-913
20.
Thur, J.,
R. Nischt,
T. Krieg, and
N. Hunzelmann.
1996.
Quantitative analysis of
1(I) procollagen transcripts in vivo by competitive polymerase
chain reaction.
Matrix Biol.
15:
49-52
[Medline].
21.
Napoli, J.,
D. Prentice,
C. Niinami,
A. Bishop,
P. Desmond, and
G. W. McCaughan.
1997.
Sequential increases in the intrahepatic expression of epidermal growth factor, basic fibroblast growth factor, and transforming
growth factor
in bile duct ligated rat model of cirrhosis.
Hepatology
26:
624-633
[Medline].
22. Peterkofsky, B., and R. Diegelmann. 1971. Use of a mixture of proteinase-free collagenases for the specific assay of radioactive collagen in the presence of other proteins. Biochemistry 10: 988-994 [Medline].
23. Leslie, K. O., J. Mitchell, and R. Low. 1992. Lung myofibroblasts. Cell Motil. Cytoskeleton 22: 92-98 [Medline].
24.
Racine-Samson, L.,
D. C. Rockey, and
D. M. Bissell.
1997.
The role of alpha
1 beta 1 integrin in wound contraction. A quantitative analysis of liver
myofibroblasts in vivo and in primary culture.
J. Biol. Chem.
272:
30911-30917
25.
Uhal, B.,
I. Joshi,
S. Mundle,
A. Raza,
A. Pardo, and
M. Selman.
1995.
Fibroblasts isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro.
Am. J. Physiol.
269:
L819-L828
26.
Uhal, B. D.,
I. Joshi,
W. F. Hughes,
C. Ramos,
A. Pardo, and
M. Selman.
1998.
Alveolar epithelial cell death adjacent to underline myofibroblasts in
advanced fibrotic human lung.
Am. J. Physiol.
275:
L1192-L1199
27. Nozaky, Y., and S. Phan. 1999. Rat lung myofibroblast differentiation results in reduced telomerase activity. Am. J. Respir. Crit. Care Med. 159: A929 .
28.
Zhang, H. Y.,
M. Gharaee-Kermani, and
S. H. Phan.
1997.
Regulation of
lung fibroblast
-smooth muscle actin expression, contractile phenotype,
and apoptosis by IL-1
.
J. Immunol.
158:
1392-1399
[Abstract].
29.
Wang, R.,
C. Ramos,
I. Joshi,
A. Zagariya,
O. Ibarra-Sunga,
A. Pardo,
M. Selman, and
B. D. Uhal.
1999.
Human lung myofibroblast-derived inducers of alveolar epithelial apoptosis identified as angiotensin peptides.
Am.
J. Physiol.
277:
L1158-L1164
30. Kajstura, J., E. Cigola, A. Malhotra, P. Li, W. Cheng, L. G. Meggs, and P. Anversa. 1997. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J. Mol. Cell. Cardiol. 29: 859-870 [Medline].
31. Brew, K., D. Dinakarpandian, and H. Nagase. 2000. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim. Biophys. Acta 1477: 267-283 [Medline].
32.
Pardo, A.,
M. Selman,
R. Ramírez,
C. Ramos,
M. Montaño,
G. Stricklin, and
G. Raghu.
1992.
Production of collagenase and tissue inhibitor of metalloproteinases by fibroblasts derived from normal and fibrotic human
lungs.
Chest
102:
1085-1089
33. Gómez, D., D. Alonso, U. Yoshiji, and U. P. Thorgeirsson. 1997. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur. J. Cell Biol. 74: 111-122 [Medline].
34. Mattila, L., K. Airola, M. Ahonen, M. Hietarinta, C. Black, U. Saarialho-Kere, and V. M. Kahari. 1998. Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts. J. Invest. Dermatol. 110: 416-421 [Medline].
35.
Dollery, C. M.,
J. R. McEwan,
M. Wang,
Q. A. Sang,
Y. E. Liu, and
Y. E. Shi.
1999.
TIMP-4 is regulated by vascular injury in rats.
Circ. Res.
84:
498-504
This article has been cited by other articles:
![]() |
P. Rogliani, M. Mura, M. Assunta Porretta, and C. Saltini Review: New perspectives in the treatment of idiopathic pulmonary fibrosis Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 75 - 93. [Abstract] [PDF] |
||||
![]() |
M. Abel and H. Vliagoftis Mast Cell-Fibroblast Interactions Induce Matrix Metalloproteinase-9 Release from Fibroblasts: Role for IgE-Mediated Mast Cell Activation J. Immunol., March 1, 2008; 180(5): 3543 - 3550. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Horowitz, D. S. Rogers, R. H. Simon, T. H. Sisson, and V. J. Thannickal Plasminogen Activation Induced Pericellular Fibronectin Proteolysis Promotes Fibroblast Apoptosis Am. J. Respir. Cell Mol. Biol., January 1, 2008; 38(1): 78 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Konigshoff, A. Wilhelm, A. Jahn, D. Sedding, O. V. Amarie, B. Eul, W. Seeger, L. Fink, A. Gunther, O. Eickelberg, et al. The Angiotensin II Receptor 2 Is Expressed and Mediates Angiotensin II Signaling in Lung Fibrosis Am. J. Respir. Cell Mol. Biol., December 1, 2007; 37(6): 640 - 650. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Burstein, X.-Y. Qi, Y.-H. Yeh, A. Calderone, and S. Nattel Atrial cardiomyocyte tachycardia alters cardiac fibroblast function: A novel consideration in atrial remodeling Cardiovasc Res, December 1, 2007; 76(3): 442 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kass, R. S. Bridges, A. Borczuk, and S. Greenberg Methionine Aminopeptidase-2 as a Selective Target of Myofibroblasts in Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol., August 1, 2007; 37(2): 193 - 201. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. NOCENTINI, S. CUZZOCREA, R. BIANCHINI, E. MAZZON, and C. RICCARDI Modulation of Acute and Chronic Inflammation of the Lung by GITR and its Ligand Ann. N.Y. Acad. Sci., June 1, 2007; 1107(1): 380 - 391. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. I. Chaudhary, G. J. Roth, F. Hilberg, J. Muller-Quernheim, A. Prasse, G. Zissel, A. Schnapp, and J. E. Park Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Eur. Respir. J., May 1, 2007; 29(5): 976 - 985. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Pierce, K. Carpenter, C. Jakubzick, S. L. Kunkel, K. R. Flaherty, F. J. Martinez, and C. M. Hogaboam Therapeutic Targeting of CC Ligand 21 or CC Chemokine Receptor 7 Abrogates Pulmonary Fibrosis Induced by the Adoptive Transfer of Human Pulmonary Fibroblasts to Immunodeficient Mice Am. J. Pathol., April 1, 2007; 170(4): 1152 - 1164. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Y. Sanders, P. Kumbla, and J. S. Hagood Enhanced Myofibroblastic Differentiation and Survival in Thy-1(-) Lung Fibroblasts Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 226 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Ramos, M. Montano, C. Becerril, J. Cisneros-Lira, L. Barrera, V. Ruiz, A. Pardo, and M. Selman Acidic fibroblast growth factor decreases {alpha}-smooth muscle actin expression and induces apoptosis in human normal lung fibroblasts Am J Physiol Lung Cell Mol Physiol, November 1, 2006; 291(5): L871 - L879. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Sinuani, Z. Averbukh, I. Gitelman, M. J. Rapoport, J. Sandbank, M. Albeck, B. Sredni, and J. Weissgarten Mesangial cells initiate compensatory renal tubular hypertrophy via IL-10-induced TGF-beta secretion: effect of the immunomodulator AS101 on this process Am J Physiol Renal Physiol, August 1, 2006; 291(2): F384 - F394. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Molina-Molina, A Serrano-Mollar, O Bulbena, L Fernandez-Zabalegui, D Closa, A Marin-Arguedas, A Torrego, J Mullol, C Picado, and A Xaubet Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis Thorax, July 1, 2006; 61(7): 604 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. I. Chaudhary, A. Schnapp, and J. E. Park Pharmacologic Differentiation of Inflammation and Fibrosis in the Rat Bleomycin Model Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 769 - 776. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Matsuyama, M. Watanabe, Y. Shirahama, H. Mitsuyama, I. Higashimoto, M. Osame, and K. Arimura Discoidin Domain Receptor 1 Contributes to the Survival of Lung Fibroblast in Idiopathic Pulmonary Fibrosis Am. J. Pathol., March 1, 2006; 168(3): 866 - 877. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Fredriksson, X. D. Liu, J. Lundahl, J. Klominek, S. I. Rennard, and C. M. Skold Red blood cells increase secretion of matrix metalloproteinases from human lung fibroblasts in vitro Am J Physiol Lung Cell Mol Physiol, February 1, 2006; 290(2): L326 - L333. [Abstract] [Full Text] [PDF] |
||||